OA

FDA Authorizes Marketing of MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Retrieved on: 
Tuesday, April 11, 2023
General Health, FDA, Medical Devices, Health, Health Technology, Duke University, I, Disease, Surgeon, Terminal, American Sports Medicine Institute, Arthritis, Arthroplasty, Quality of life, Cartilage, Multimedia, Doctor of Philosophy, Trial of the century, Pain, OA, Hospital for Special Surgery, TKA, Standard of care, Patient, ISA, Joint, Hospital, Meniscus, Chronic pain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hip, Safety, Food, Knee, Pharmaceutical industry

Moximed , a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) granted marketing authorization of the MISHA™ Knee System, an implantable shock absorber (ISA) for the knee.

Key Points: 
  • Moximed , a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) granted marketing authorization of the MISHA™ Knee System, an implantable shock absorber (ISA) for the knee.
  • View the full release here: https://www.businesswire.com/news/home/20230410005434/en/
    “I've been lucky enough to have been exposed to many major orthopedic innovations, most notably total knee arthroplasty (TKA).
  • For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease.
  • OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.

United States Open Access Journal Publishing Market Report 2022-2026 Featuring Major Players Such as John Wiley & Sons, Springer Nature, Wolters Kluwer, Oxford University Press Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, April 10, 2023
Communications, Publishing, Policy, OA, Microsoft Access, Intelligence, World Publishing Company, Public policy, Research, Open access, Consultant, Hybrid open-access journal, Video game, Cryptocurrency

The "United States Open Access Journal Publishing 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Open Access Journal Publishing 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • Rely on the Open Access Journal Publishing 2022-2026 to build your growth plan for this year and beyond.
  • This report explains the origins of the open access movement, gives a timeline for its development, but most importantly, the publisher quantifies open access' position as a fast growing subsegment of scholarly journal publishing.
  • Open Access Journal Publishing 2022-2026 contains separate chapters covering the market, key competitors, and issues and forecast that include:
    A breakdown of players in the open access ecosystem including public and private research funders.

ConcertAI's TeraRecon Brings Osteoarthritis and Fracture Detection to the Eureka Clinical AI Platform with Radiobotics Partnership

Retrieved on: 
Tuesday, April 4, 2023
Skeleton, Osteoarthritis, CE, X-ray, University, Disability, Hip, Radiology, Associate, OA, Hospital, Patient, Fracture, Algorithm, PACS, Diagnosis, AI, Cardiology, Elective surgery, FDA, Health, UTHealth School of Dentistry, Neurology, Knee, Disease, Medical imaging, Medical device

CAMBRIDGE, Mass., April 4, 2023 /PRNewswire/ -- ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS category leader, has partnered with Radiobotics to provide the state-of-the-art artificial intelligence and machine learning applications RBknee™ (FDA cleared and CE marked) and RBFracture™ (CE marked) for users of the Eureka Clinical AI platform.

Key Points: 
  • Radiobotics applications on the Eureka Clinical AI platform integrate seamlessly within existing medical workflows and can serve hospitals, radiologists, orthopedic surgeons and, ultimately, patients by automating medical image analysis.
  • "We are thrilled to offer RBFracture and RBknee on the Eureka Clinical AI platform, a streamlined, best-in-breed ecosystem."
  • Eureka Clinical AI is the leading AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI's TeraRecon.
  • Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more at www.terarecon.com/artificial-intelligence

Anika Files Preliminary Proxy Statement

Retrieved on: 
Monday, March 27, 2023
Elective surgery, Annual Meetings of the International Monetary Fund and the World Bank Group, OA, Annual general meeting, Growth, Security (finance), R, Joint, Therapy, III, Holding company, Shareholder

In its preliminary proxy statement, the Anika Board of Directors recommends that shareholders vote for the re-election of its two nominees — John Henneman, III and Susan Vogt — at the Annual Meeting.

Key Points: 
  • In its preliminary proxy statement, the Anika Board of Directors recommends that shareholders vote for the re-election of its two nominees — John Henneman, III and Susan Vogt — at the Annual Meeting.
  • The Anika Board believes that electing either of Caligan’s candidates would jeopardize the value of its shareholders’ investment in the Company.
  • Anika’s preliminary proxy materials can be found on the SEC’s website at www.sec.gov as well as on the Company’s website at https://ir.anika.com/ .
  • The Anika Board recommends that shareholders discard any proxy materials from Caligan and vote using the WHITE proxy card they will receive as part of the definitive proxy materials that will be delivered by the Company.

Science By All, For All: AIP Publishing Expands APC Waiver and Discount Policy

Retrieved on: 
Thursday, March 23, 2023
Group A, Learning, Science, Communication, AIP, Policy, Charge, Research, Multimedia, World Bank, Open access, Vance, OA, American Institute of Physics, Gold, Publishing, APC, Pharmaceutical industry

The move is reflective of AIP Publishing's continued efforts to improve the accessibility and inclusivity of scholarly publishing.

Key Points: 
  • The move is reflective of AIP Publishing's continued efforts to improve the accessibility and inclusivity of scholarly publishing.
  • By expanding our APC Waiver and Discount Policy, AIP Publishing removes barriers and opens doors.
  • AIP Publishing's APC Waiver and Discount Policy for Gold OA titles expands upon the previously adopted Research4Life guidelines, with eligible countries classified as either Group A (full waiver) or Group B (discounts).
  • To see the full lists of countries eligible for APC waivers and discounts through AIP Publishing, please visit our Open Access Publishing Options page .

Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress

Retrieved on: 
Monday, March 20, 2023
Gait analysis, DNA, Plasmid, Orthopaedic Research Society, Journal of Orthopaedic Research, Osteoarthritis, ROM, Gait, Interleukin, Preferred walking speed, Ageing, MBA, Inflammation, Fritz Köberle, Walking, Homeostasis, OA, Congress, Patient, Immune system, OARSI, World Congress, Therapy, Arnold, Osteoarthritis Research Society International, Shipbuilding, Pharmaceutical industry, Medical imaging

NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, today announced pooled gait data from a world-renowned gait laboratory in Adelaide, Australia, which served as a study site for two studies of lead candidate XT-150 in patients with knee osteoarthritis (OA). XT-150 is a locally injectable plasmid DNA (pDNA)-delivered gene therapy expressing IL-10v, a proprietary modified version of interleukin-10 (IL-10), which Xalud is evaluating across a broad range of chronic inflammatory diseases in clinical and preclinical studies.

Key Points: 
  • The results demonstrate a positive signal supporting the use of XT-150 as a potential effective treatment in knee OA with the goal of improving joint function.
  • The data were presented in a poster presentation titled “Functional improvements in knee kinematics during walking gait over six months following treatment with XT-150: pooled results from two clinical trials” at the 2023 Osteoarthritis Research Society International (OARSI) World Congress.
  • We believe that this supplements the body’s own IL-10 activity and may restore immune system homeostasis in chronic inflammatory diseases such as knee OA.
  • Xalud has included gait analysis as part of its multi-study development program to provide functional assessment in addition to patient reported outcomes.

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on: 
Monday, March 20, 2023
Immortalised cell line, COPD, Osteoarthritis, Osteoporosis, Disease, Arthropathy, Woman, Cartilage, Research, APPA, Biomedical Research, Inflammation, Cell, Chronic obstructive pulmonary disease, AKL, Pain, Degenerative disease, Knee, Cellular senescence, Patent, Patient, Senescence, Parkinson's disease, Joint, OARSI, Alzheimer's disease, World Congress, Therapy, Notifiable disease, Osteoarthritis Research Society International, Frailty, Pharmaceutical industry, OA

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points: 
  • STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
    The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
    Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
    "Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
  • "8
    As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
    Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
    David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
  • With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
  • APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
    There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on: 
Monday, March 20, 2023
Immortalised cell line, COPD, Osteoarthritis, Osteoporosis, Disease, Arthropathy, Woman, Cartilage, Research, APPA, Biomedical Research, Inflammation, Cell, Chronic obstructive pulmonary disease, AKL, Pain, Degenerative disease, Knee, Cellular senescence, Patent, Patient, Senescence, Parkinson's disease, Joint, OARSI, Alzheimer's disease, World Congress, Therapy, Notifiable disease, Osteoarthritis Research Society International, Frailty, Pharmaceutical industry, OA

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points: 
  • STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
    The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
    Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
    "Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
  • "8
    As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
    Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
    David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
  • With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
  • APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17 Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
    There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24

Physician Growth Partners advises Ohio-based Precision Orthopaedic Specialties and Chardon Surgery Center in transaction with Ortho Alliance

Retrieved on: 
Thursday, March 16, 2023
MSO, Sports medicine, Partnership, OA, Chiropractic, Economics, Physician, PGP, Marketing, Growth, Podiatry, Partner (business rank), Dentistry

CHICAGO, March 16, 2023 (GLOBE NEWSWIRE) -- Physician Growth Partners (“PGP”) is pleased to have advised Ohio-based Precision Orthopaedic Specialties and Chardon Surgery Center , (collectively “Precision Ortho”), in its recent transaction with Ortho Alliance , (“OA”) a private equity backed orthopaedic platform and portfolio company of Revelstoke Capital Partners .

Key Points: 
  • CHICAGO, March 16, 2023 (GLOBE NEWSWIRE) -- Physician Growth Partners (“PGP”) is pleased to have advised Ohio-based Precision Orthopaedic Specialties and Chardon Surgery Center , (collectively “Precision Ortho”), in its recent transaction with Ortho Alliance , (“OA”) a private equity backed orthopaedic platform and portfolio company of Revelstoke Capital Partners .
  • Led by a group of highly experienced and sophisticated physicians, Precision Ortho has three offices and one multi-specialty surgery center in Northeast Ohio.
  • Their team is comprised of more than 10 physicians and 50+ staff providing orthopaedic and spinal surgery, podiatry, sports medicine, chiropractic, and physical therapy services.
  • Physician Growth Partners served as the exclusive transaction advisor to Precision Orthopaedic Specialties and Chardon Surgery Center in its evaluation, negotiation, and execution of this transaction.

Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Steps, Elective surgery, Pain, Webcast, Ankle, Anika, Acquisition, Growth, Sports medicine, Shoulder, Surgeon, Therapy, Patient, Rationalization, FDA, PMA, DePuy Synthes, OA, Medical device, Video game, Rail freight transport, Reinsurance, Poultry farming, Dentistry, Birth control, Pharmaceutical industry, Nursing

Revenue in the fourth quarter of 2022 was $39.6 million, up 11% compared with $35.8 million in the fourth quarter of 2021.

Key Points: 
  • Revenue in the fourth quarter of 2022 was $39.6 million, up 11% compared with $35.8 million in the fourth quarter of 2021.
  • Adjusted EBITDA2 was $1.4 million, compared to adjusted EBITDA2 of ($0.2) million in the fourth quarter of 2021.
  • Operating cash flow was $0.5 million; quarter ending cash balance was $86.3 million with no outstanding debt.
  • “We delivered strong operational and financial performance in the fourth quarter, building momentum for Anika’s multi-year growth strategy,” said Cheryl R. Blanchard, Ph.D., Anika’s President and CEO.